Finance

Lists
Why is CRL up 5.14%?
Dive Deeper
CRL:NYSE
Charles River Laboratories Intrtnl, Inc.
$ 315.45
+5.14%
(+15.43) 1D
$ 315.45
0.00% (0.00)
After hours
Closed: 10-р сарын 20, 16:00:07 (GMT-4)  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRL...
Open
$ 308.84
High
$ 317.59
Low
$ 304.00
Mkt. cap
15.06 тэрбум
Avg. vol.
971.54 мян
Volume
1.27 сая
52-wk high
$ 333.30
52-wk low
$ 146.20
EPS
-$ 4.85
Beta
1.40
Shares outstanding
47.74 сая
No. of employees
19 мян
Open
$ 308.84
High
$ 317.59
Low
$ 304.00
Mkt. cap
15.06 тэрбум
Avg. vol.
971.54 мян
Volume
1.27 сая
52-wk high
$ 333.30
52-wk low
$ 146.20
EPS
-$ 4.85
Beta
1.40
Shares outstanding
47.74 сая
No. of employees
19 мян
News stories
From web sources and news partners
Profile
Charles River Laboratories International, Incorporated is an American life sciences company and contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides goods and services that support the development of drugs, vaccines, and other therapeutics. Its operations span at least 20 countries, offering research models, drug discovery and safety assessment, and manufacturing and testing services to pharmaceutical, biotechnology, government, and other clients. Charles River Laboratories is a global provider of non-clinical drug development services, known for its role in toxicology studies, research animal models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of research animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
About Charles River Laboratories Intrtnl, Inc.
CEO-
Employees19 мян
Founded1947
HeadquartersWilmington, Массачусеттс, Америкийн Нэгдсэн Улс
SectorHealth care
Websitecriver.com
Analyst ratings
Based on 15 analysts giving stock ratings to CRL in the past 3 months
Strong buy
Buy
14
Hold
1
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for CRL in the last 3 months.
Highest
Current $ 315.45
$ 357.00 (+13.17%)
Average
$ 329.85 (+4.56%)
Lowest
$ 295.00 (-6.48%)
Analyst
Recommendation
Action
Price target
Projected
Date
Casey Woodring
J.P. Morgan
Buy
Maintained
$ 345.00
+9.4%
10/16/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Reiterated
$ 340.00
+7.8%
10/13/2026
Ryan Halsted
RBC Capital
Buy
Maintained
$ 322.00
+2.1%
10/06/2026
Kevin Caliendo
UBS
Buy
Initiated
$ 357.00
+13.2%
09/30/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
-
-
09/28/2026
David Windley
Jefferies
Buy
Maintained
$ 340.00
+7.8%
09/28/2026
Justin Bowers
Deutsche Bank
Buy
Reiterated
$ 320.00
+1.4%
09/25/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
$ 330.00
+4.6%
09/25/2026
Ann Hynes
Mizuho Securities
Hold
Maintained
$ 295.00
-6.5%
09/25/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
$ 334.00
+5.9%
09/25/2026
Luke Sergott
Barclays
Buy
Maintained
$ 330.00
+4.6%
09/24/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
$ 325.00
+3%
09/25/2026
Jared Haase
William Blair
Buy
Reiterated
-
-
09/24/2026
Unknown Analyst
Stephens
Buy
Initiated
$ 320.00
+1.4%
09/22/2026
David Toung
Argus Research
Buy
Reiterated
$ 330.00
+4.6%
09/16/2026
Michael Luo CFA
CLSA
Hold
Downgraded
$ 219.00
-30.6%
07/20/2026
Patrick B Donnelly
Citi
Buy
Maintained
$ 265.00
-16%
07/08/2026
Max Smock
William Blair
Buy
Maintained
-
-
06/02/2026
Charles Weston
RBC Capital
Buy
Initiated
$ 215.00
-31.8%
04/13/2026
Dan Leonard
UBS
Hold
Maintained
$ 175.00
-44.5%
02/25/2026
Last report
2026 оны 8-р сарын 5
Fiscal period
Q2 2026
$ 3.02 / $ 2.74
+10.31%beat
Revenue / Est. (USD)
1.00 тэрбум / 977.20 сая
+2.75%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
1.00 тэрбум
994.23 сая
995.83 сая
1.00 тэрбум
Cost of goods sold
652.72 сая
665.36 сая
672.79 сая
625.06 сая
Cost of revenue
652.72 сая
665.36 сая
672.79 сая
625.06 сая
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
173.64 сая
192.02 сая
149.12 сая
214.18 сая
Operating expense
201.05 сая
284.04 сая
164.46 сая
227.27 сая
Total operating expenses
853.77 сая
949.40 сая
837.25 сая
852.33 сая
Operating income
151.08 сая
44.83 сая
158.58 сая
151.74 сая
Other non operating income
-22.62 сая
27.72 сая
-123.11 сая
25.99 сая
EBT including unusual items
87.20 сая
-294.10 сая
-29.94 сая
53.17 сая
EBT excluding unusual items
104.48 сая
35.18 сая
8.62 сая
148.43 сая
Income tax expense
31.64 сая
-17.81 сая
-15.14 сая
53.93 сая
Effective tax rate
36.29%
6.06%
50.56%
101.43%
Other operating expenses
-
-
-
-
Net income
54.42 сая
-276.56 сая
-14.84 сая
-1.48 сая
Net profit margin
5.42%
-27.82%
-1.49%
-0.15%
Earnings per share
2.43
2.39
2.06
3.02
Interest and investment income
1.42 сая
1.02 сая
1.03 сая
1.03 сая
Interest expense
-25.40 сая
-23.78 сая
-26.74 сая
-30.34 сая
Net interest expenses
-23.98 сая
-22.76 сая
-25.71 сая
-29.31 сая
Depreciation and amortization charges
-
-
-
-
EBITDA
236.25 сая
169.61 сая
225.73 сая
217.54 сая
Gain or loss from assets sale
-
-
117.98 сая
24.92 сая
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google аппс